CCR5 and metabolic dysfunction-associated steatohepatitis: In patients in a phase 2b study, cenicriviroc (CVC), a dual CCR2/CCR5 inhibitor, was reported to be most efficacious in patients with more advanced degrees of NASH-associated fibrosis (CENTAUR study; NCT02217475).